Transaction DateRecipientSharesTypePriceValue
17th February 2021Peter A. Thompson1,285,714Open or private purchase$3.50$4,499,999.00
12th February 2021Carl L Gordon104,050Grant/award etc.$13.00$1,352,650.00
12th February 2021Advisors Llc Orbimed104,050Grant/award etc.$13.00$1,352,650.00
12th February 2021Advisors Llc Orbimed420,299Grant/award etc.$13.00$5,463,887.00
12th February 2021Carl L Gordon420,299Grant/award etc.$13.00$5,463,887.00
9th February 2021Advisors Llc Orbimed190,000Open or private purchase$17.00$3,230,000.00
9th February 2021Advisors Llc Orbimed285,000Open or private purchase$17.00$4,845,000.00
9th February 2021Carl L Gordon1,989,723Conversion of derivative$0.00
9th February 2021Carl L Gordon1,326,481Conversion of derivative$0.00
9th February 2021Carl L Gordon285,000Open or private purchase$17.00$4,845,000.00
Prevail Therapeutics
Prevail Therapeutics logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.


Prevail Therapeutics, Inc. develops therapeutics for neurodegenerative diseases. The company was founded by Asa Abeliovich on July 6, 2017 and is headquartered in New York, NY.


Ticker: PRVL
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1714798
Employees: 55
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals